Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Hemay007 in Patients With Moderate to Severe Rheumatoid Arthritis

NCT05247216 is registered in ClinicalTrials.gov with Tianjin Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT05247216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05247216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Hemay007 in Patients With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
March 26, 2021
Completion date
June 22, 2023
Enrollment
140 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis